161 related articles for article (PubMed ID: 31163009)
1. Treatment-Related Toxicity Using Prostate-Only Versus Prostate and Pelvic Lymph Node Intensity-Modulated Radiation Therapy: A National Population-Based Study.
Parry MG; Sujenthiran A; Cowling TE; Nossiter J; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
J Clin Oncol; 2019 Jul; 37(21):1828-1835. PubMed ID: 31163009
[TBL] [Abstract][Full Text] [Related]
2. National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer.
Sujenthiran A; Nossiter J; Charman SC; Parry M; Dasgupta P; van der Meulen J; Cathcart PJ; Clarke NW; Payne H; Aggarwal A
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1253-1260. PubMed ID: 28974414
[TBL] [Abstract][Full Text] [Related]
3. Toxicity of Pelvic Lymph Node Irradiation With Intensity Modulated Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer: A National Population-Based Study Using Patient-Reported Outcomes.
Parry MG; Nossiter J; Cowling TE; Sujenthiran A; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1196-1203. PubMed ID: 32717261
[TBL] [Abstract][Full Text] [Related]
4. Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL).
Dearnaley D; Griffin CL; Lewis R; Mayles P; Mayles H; Naismith OF; Harris V; Scrase CD; Staffurth J; Syndikus I; Zarkar A; Ford DR; Rimmer YL; Horan G; Khoo V; Frew J; Venkitaraman R; Hall E
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):605-617. PubMed ID: 30528653
[TBL] [Abstract][Full Text] [Related]
5. Treatment-related toxicity using prostate bed versus prostate bed and pelvic lymph node radiation therapy following radical prostatectomy: A national population-based study.
Sujenthiran A; Parry MG; Dodkins J; Nossiter J; Morris M; Berry B; Nathan A; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Clin Transl Radiat Oncol; 2023 May; 40():100622. PubMed ID: 37152844
[TBL] [Abstract][Full Text] [Related]
6. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
7. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
[TBL] [Abstract][Full Text] [Related]
8. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
9. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
[TBL] [Abstract][Full Text] [Related]
10. Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting.
Santos PMG; Barsky AR; Hwang WT; Deville C; Wang X; Both S; Bekelman JE; Christodouleas JP; Vapiwala N
Cancer; 2019 Dec; 125(23):4278-4293. PubMed ID: 31503338
[TBL] [Abstract][Full Text] [Related]
11. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
12. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.
Habl G; Katayama S; Uhl M; Kessel KA; Edler L; Debus J; Herfarth K; Sterzing F
BMC Cancer; 2015 Nov; 15():868. PubMed ID: 26547188
[TBL] [Abstract][Full Text] [Related]
13. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
Guckenberger M; Baier K; Richter A; Vordermark D; Flentje M
Radiat Oncol; 2008 Jan; 3():3. PubMed ID: 18190681
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ
Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170
[TBL] [Abstract][Full Text] [Related]
15. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
16. Treatment-related toxicity in men who received Intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: A national population-based study.
Sujenthiran A; Nossiter J; Parry M; Charman SC; Cathcart PJ; van der Meulen J; Clarke NW; Payne H; Aggarwal A
Radiother Oncol; 2018 Aug; 128(2):357-363. PubMed ID: 29773442
[TBL] [Abstract][Full Text] [Related]
17. Volumetric Modulated Arc Therapy of the Pelvic Lymph Nodes to the Aortic Bifurcation in Higher Risk Prostate Cancer: Early Toxicity Outcomes.
Hesselberg G; Fogarty G; Haydu L; Dougheney N; Stricker P
Biomed Res Int; 2015; 2015():696439. PubMed ID: 26539522
[TBL] [Abstract][Full Text] [Related]
18. Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition.
Ganswindt U; Paulsen F; Corvin S; Eichhorn K; Glocker S; Hundt I; Birkner M; Alber M; Anastasiadis A; Stenzl A; Bares R; Budach W; Bamberg M; Belka C
BMC Cancer; 2005 Jul; 5():91. PubMed ID: 16048656
[TBL] [Abstract][Full Text] [Related]
19. Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer.
Choo R; Hillman DW; Mitchell C; Daniels T; Vargas C; Rwigema JC; Corbin K; Keole S; Vora S; Merrell K; Stish B; Pisansky T; Davis BJ; Amundson A; Wong W
Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1085-1094. PubMed ID: 36427645
[TBL] [Abstract][Full Text] [Related]
20. Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.
Reis Ferreira M; Khan A; Thomas K; Truelove L; McNair H; Gao A; Parker CC; Huddart R; Bidmead M; Eeles R; Khoo V; van As NJ; Hansen VN; Dearnaley DP
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1234-1242. PubMed ID: 28939224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
